Insulin Delivery Devices Pipeline Technology and Market Forecasts to 2015

Insulin Delivery Devices Pipeline Technology and Market Forecasts to 2015

Insulin Delivery Devices Pipeline Technology and Market Forecasts to 2015

Summary

GlobalData’s “Insulin Delivery Devices Pipeline Technology and Market Forecasts to 2015” report is an essential source of information and analysis on the global insulin delivery devices market. The report identifies the key trends shaping and driving the dynamism in the global insulin delivery devices market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global insulin delivery devices sector.

Scope

- Annualized global insulin delivery devices market revenues data from 2001 to 2008, forecast forward for 7 years to 2015. Updated company shares data for 2008.
- Key categories covered in this report are insulin pumps, insulin pens and insulin syringes
- Analysis and review of the key events and milestones that will impact the future of the global insulin delivery devices market. Each trend independently researched to provide qualitative analysis of what the implications on sectors are, and how are companies responding to these trends.
- Insightful review of key industry drivers, restraints and challenges which are likely to impact the global insulin delivery devices market in the long run.
- The report also covers information on the leading market players, the competitive landscape, and the leading pipeline products and technologies. Key companies covered include Becton, Dickinson and Company, Medtronic, F. Hoffmann La Roche, Novo Nordisk, Sanofi Aventis, Eli Lilly, and Animas Corporation
- Comprehensive analysis of the most likely developments expected to bring a shift to the market positions of the leading manufacturers.
- The report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global insulin delivery devices market.
- Identify key players best positioned to take advantage of the emerging market opportunities by developing insight on the prevalent and anticipated competitive landscape.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global insulin delivery devices market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- Support your go/non-go dilemma by identifying the markets that are least competitive and present significant opportunities for innovation and growth.
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.

Table Of Contents

1 Table Of Contents
1 Table Of Contents 2
1.1 List of Tables 6
1.2 List of Figures 7
2 Insulin Delivery Devices Pipeline Technology and Market Forecasts to 2015 8
2.1 Executive Summary 8
3 Insulin Delivery Devices Technology Landscape 10
3.1 Overview 10
3.2 History 11
3.3 Emerging Trends 11
3.3.1 Artificial Pancreas 11
3.3.2 MEMS Technology for Insulin Delivery 11
3.3.3 Transdermal Delivery and Insulin Patch 11
3.3.4 Inhaled Insulin 12
3.3.5 Oral Insulin 12
4 Global Insulin Delivery Devices Market Characterization 13
4.1 Market Overview 13
4.2 Insulin Delivery Devices Market Size 13
4.3 Insulin Delivery Devices Market Forecast and CAGR 14
4.4 Insulin Syringes Market Forecast and CAGR 18
4.5 Insulin Pens Market Forecast and CAGR 20
4.6 Insulin Pumps Market Forecast and CAGR 22
4.7 Market Dynamics 24
4.7.1 Market Drivers 24
4.7.1.1 Large diabetic population worldwide driving insulin delivery devices market 24
4.7.1.2 Increasing ageing and obese population contribution to diabetes epidemic 24
4.7.1.3 Technological advancements will drive the insulin delivery devices market 24
4.7.2 Market Restraints 25
4.7.2.1 Low diagnosis rate 25
4.7.2.2 Low patient compliance 25
4.7.2.3 Reimbursement and overall cost is a restraint for insulin pens and pumps 25
4.8 Insulin Delivery Devices Cross Country Analysis 26
4.9 Insulin Delivery Devices Cross Segment Analysis 28
4.10 Opportunity and Unmet Need 30
4.11 Key Takeaway 32
5 Insulin Delivery Devices Competitive Landscape 33
5.1 Overview 33
5.2 Strategic Competitor Assessment 33
5.3 Insulin Delivery Devices Company Shares 35
5.3.1 Becton, Dickinson and Company 35
5.3.2 Medtronic 35
5.3.3 Novo Nordisk 36
5.3.4 Others 36
5.3.4.1 Insulet Corporation 36
5.3.4.2 NiliMEDIX 36
5.3.4.3 Medingo Ltd. 37
5.3.4.4 Debiotech S.A 37
5.3.4.5 Phluid Corporation 37
5.3.4.6 Ratio Inc. 37
5.3.4.7 Insuline Medical Ltd. 37
5.3.4.8 Aradigm Corporation 37
5.3.4.9 MannKind Corporation 38
5.3.4.10 Altea Therapeutics Corporation 38
5.4 Key Takeaway 38
6 Insulin Delivery Devices Pipeline Products 39
6.1 Overview 39
6.2 Strategic Pipeline Assessment 39
6.3 Insulin Delivery Devices – Clinical Pipeline by Mode of Insulin Delivery 42
6.4 Insulin Delivery Devices – Pipeline by Clinical Phase of Development 43
6.5 Global Insulin Delivery Devices Pipeline Product Summary 44
6.6 Insulin Delivery Devices – Promising Devices under Clinical Development 45
6.6.1 Closed-loop diabetes management system 45
6.6.1.1 Product Status 45
6.6.1.2 Product Description 45
6.6.2 Paradigm Veo System 46
6.6.2.1 Product Status 46
6.6.2.2 Product Description 46
6.6.3 AERx insulin Diabetes Management System 47
6.6.3.1 Product Status 47
6.6.3.2 Product Description 47
6.6.3.3 Clinical Trial One 48
6.6.3.4 Clinical Trial Two 49
6.6.3.5 Clinical Trial Three 50
6.7 Key Takeaway 51
7 Insulin Delivery Devices – Future Market Competition 52
7.1 Strategic Competitor Assessment 53
8 Reimbursement for Insulin Delivery Devices 54
9 Appendix 56
9.1 Market Definitions 56
9.1.1 Insulin Delivery 56
9.1.1.1 Insulin Pens 56
9.1.1.2 Insulin Pumps 57
9.1.1.3 Insulin Syringes 57
9.1.1.4 Traditional Insulin Pump Accessories 57
9.2 Abbreviations 57
9.3 Research Methodology 58
9.4 Secondary Research 59
9.5 Primary Research 59
9.6 Models 60
9.7 Forecasts 60
9.8 Expert Panels 60
9.9 GlobalData Consulting 61
9.10 Contact Us 61
9.11 Disclaimer 61

Table Of Tables

1.1 List of Tables
Table 1: Comparison of Insulin Delivery Devices 10
Table 2: Insulin Delivery Devices, Revenue, Global, 2000-2008 15
Table 3: Insulin Delivery Devices, Global, Revenue ($ m), 2008-2015 17
Table 4: Insulin Syringes, Global, Revenue ($ m), 2000-2008 18
Table 5: Insulin Syringes, Global, Revenue ($ m), 2008-2015 19
Table 6: Insulin Pens, Global, Revenue ($ m), 2000-2008 20
Table 7: Insulin Pens, Global, Revenue ($ m), 2008-2015 21
Table 8: Insulin Pumps, Global, Revenue ($ m), 2000-2008 22
Table 9: Insulin Pumps, Global, Revenue ($ m), 2008-2015 23
Table 10: Insulin Delivery Devices Cross Country Analysis of Revenue, 2000-2015 27
Table 11: Insulin Delivery Devices Cross Segment Analysis of Revenue, 2000-2015 28
Table 12: Global Insulin Delivery Devices Pipeline Product Summary 44
Table 13: Closed-loop diabetes management system, Product Status 45
Table 14: Closed-loop diabetes management system, Product Description 45
Table 15: Paradigm Veo System, Product Status 46
Table 16: Paradigm Veo System, Product Description 46
Table 17: AERx insulin Diabetes Management System, Product Status 47
Table 18: AERx insulin Diabetes Management System, Product Description 47
Table 19: AERx insulin Diabetes Management System - Effect of Inhaled Insulin (AERx iDMS) Plus Pioglitazone Versus Pioglitazone Alone on HbA1c in Subjects With Type 2 Diabetes 48
Table 20: AERx insulin Diabetes Management System - Inhaled Pre-Prandial Human Insulin With the AERx iDMS Versus s.c. Insulin Aspart in Type 2 Diabetes: A 104 Week, Open-Label, Multicenter, Randomized, Trial Followed by a 12 Week re-Randomized Extension to Investigate Safety and Efficacy 49
Table 21: AERx insulin Diabetes Management System - Inhaled Mealtime Insulin With the AERx iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomized, Parallel Trial (Followed by a Twelve-Week Re-Randomized Extension) To Investigate Safety and Efficacy 50

Table Of Figures

1.2 List of Figures
Figure 1: History of Insulin Delivery Devices 11
Figure 2: Insulin Delivery Devices, Revenue, Global, 2000-2008 14
Figure 3: Insulin Delivery Devices, Global, Revenue ($ m), 2008-2015 16
Figure 4: Insulin Syringes, Global, Revenue ($ m), 2000-2008 18
Figure 5: Insulin Syringes, Global, Revenue ($ m), 2008-2015 19
Figure 6: Insulin Pens, Global, Revenue ($ m), 2000-2008 20
Figure 7: Insulin Pens, Global, Revenue ($ m), 2008-2015 21
Figure 8: Insulin Pumps, Global, Revenue ($ m), 2000-2008 22
Figure 9: Insulin Pumps, Global, Revenue ($ m), 2008-2015 23
Figure 10: Insulin Delivery Devices Cross Country Analysis of Revenue, 2000-2015 26
Figure 11: Insulin Delivery Devices Cross Segment Analysis of Revenue, 2000-2015 28
Figure 12: Opportunity and Unmet Need 31
Figure 13: Strategic Competitive Assessment 34
Figure 14: Global Insulin Delivery Devices Market, Company Share (%), 2008 35
Figure 15: Technology Trends Analytic Framework 40
Figure 16: Technology Trends Analytic Framework - Descriptions 41
Figure 17: Insulin Delivery Devices – Clinical Pipeline by Mode of Insulin Delivery 42
Figure 18: Insulin Delivery Devices Pipeline by Clinical Phase of Development 43
Figure 19: Strategic Competitor Assessment 53
Figure 20: Reimbursement for Insulin Delivery Devices 54
Figure 21: Reimbursement Mix – Insulin Pens 55
Figure 22: GlobalData Methodology 58